China Approves the World's First CAR-T Cell Therapy for Solid Tumors

For more than a decade, CAR-T cell therapy has transformed the treatment of blood cancers like leukemia and lymphoma. But solid tumors — which account for roughly 90% of all cancers — have remained stubbornly out of reach. That changed on June 22, 2026.

On that date, China's National Medical Products Administration (NMPA) approved CARsgen Therapeutics' satri-cel (satricabtagene autoleucel, CT041) for Claudin18.2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is the first CAR-T cell therapy approved anywhere in the world for a solid tumor .

Here is what makes this approval a breakthrough, how the therapy works, and what the clinical data shows.

What satri-cel is and how it targets solid tumors

Satri-cel is an autologous CAR-T cell therapy — meaning it is manufactured from a patient's own immune cells. A patient's T cells are collected, genetically engineered in a laboratory to carry a chimeric antigen receptor (CAR) that recognizes Claudin18.2 (CLDN18.2), and then infused back into the patient .

Claudin18.2 is a tight-junction protein that is commonly overexpressed on the surface of gastric, GEJ, and pancreatic cancer cells but is minimally expressed in normal tissues. This makes it an attractive target for a therapy designed to kill tumor cells while largely sparing healthy cells .

The approved indication is for:

• Claudin18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
• in patients who have failed at least two prior lines of systemic therapy

The pivotal Phase II trial (CT041-ST-01)

The clinical basis for the approval was the Phase II CT041-ST-01 trial (NCT04581473), an open-label, multicenter, randomized study. It enrolled 156 patients with CLDN18.2-positive advanced G/GEJ cancer who had already received at least two prior treatments . The results were published in The Lancet and presented at the 2025 ASCO Annual Meeting .

Efficacy Endpoint	Satri-cel	Control (Physician's Choice Chemotherapy)
Median Progression-Free Survival (PFS)	3.25 months (95% CI: 2.86–4.53)	1.77 months (95% CI: 1.61–2.04); hazard ratio 0.37
Median Overall Survival (OS)	7.92 months	5.49 months (hazard ratio 0.69)
Overall Response Rate (ORR)	38.8%	Significantly lower
Disease Control Rate (DCR)	91.8%	Not reported for control

The trial met its primary endpoint: satri-cel significantly prolonged progression-free survival compared to standard therapy, with a hazard ratio of 0.37, meaning a 63% reduction in the risk of disease progression or death at the time of analysis . Overall survival also showed a clinically meaningful improvement .

Regulatory pathway: A fast track to approval

Satri-cel moved through the Chinese regulatory system on an accelerated timeline:

• September 2020 – U.S. FDA granted Orphan Drug Designation for gastric/GEJ cancer .
• January 2022 – U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation .
• March 2025 – China's NMPA granted Breakthrough Therapy Designation (BTD) .
• May 28, 2025 – NMPA granted Priority Review status .
• Late June 2025 – NMPA formally accepted the New Drug Application (NDA) for review .
• June 22, 2026 – NMPA approval .

What this means for cell therapy and for China

Satri-cel's approval is not just a milestone for a single drug. It has broader implications:

1. Proving CAR-T can work in solid tumors. Until now, CAR-T had been spectacularly effective in hematologic malignancies but had largely failed in solid tumors, which have a hostile tumor microenvironment. Satri-cel demonstrates that with the right molecular target (Claudin18.2) and optimized CAR design, durable responses in solid tumors are achievable .

2. Cementing China's leadership in cell therapy. China now has 6–8 NMPA-approved CAR-T products covering hematologic indications, and satri-cel is the first to break into solid tumors . China has the world's most active CAR-T clinical pipeline and manufacturing costs that are approximately 30–60% of U.S. pricing, making it a global hub for cell therapy development .

3. Opening a regulatory path for other solid tumor CAR-Ts. This approval sets a regulatory precedent in China that paves the way for other solid tumor candidates targeting mesothelin, GPC3, EGFR, and other antigens .

Important caveats

While the approval is historic, it is limited to China. Satri-cel has not yet received U.S. FDA or European Medicines Agency (EMA) approval. The FDA has granted it Orphan Drug and RMAT designations, but a global Phase III or bridging trial may still be required for U.S. marketing authorization . In addition, the long-term survival data remains early, and real-world durability will need to be confirmed as patients are followed post-approval.

The bottom line

Satri-cel is the first CAR-T cell therapy approved for any solid tumor — an achievement that represents a genuine scientific and regulatory milestone. For the millions of patients with advanced gastric cancer worldwide who have exhausted standard options, it offers a new, mechanistically distinct approach. And for the field of cell therapy, it proves that the solid tumor barrier can finally be breached.